Capricor Therapeutics Inc. (CAPR) announced Friday morning that 6-month data from its Phase II clinical trial of CAP-1002 demonstrated a low probability of achieving a statistically-significant difference in the 12-month primary efficacy endpoint.
from RTT - Before the Bell http://ift.tt/2pBFHyC
via IFTTT
No comments:
Post a Comment